These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 32326087)

  • 1. Recent Synthetic Approaches towards Small Molecule Reactivators of p53.
    Silva JL; Lima CGS; Rangel LP; Ferretti GDS; Pauli FP; Ribeiro RCB; da Silva TB; da Silva FC; Ferreira VF
    Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32326087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant p53 reactivation by small molecules makes its way to the clinic.
    Bykov VJ; Wiman KG
    FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild type p53 reactivation: from lab bench to clinic.
    Selivanova G
    FEBS Lett; 2014 Aug; 588(16):2628-38. PubMed ID: 24726725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Small-Molecule Inhibitors of the p53-MDM2 Protein-Protein Interaction.
    Beloglazkina A; Zyk N; Majouga A; Beloglazkina E
    Molecules; 2020 Mar; 25(5):. PubMed ID: 32156064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.
    Hiraki M; Hwang SY; Cao S; Ramadhar TR; Byun S; Yoon KW; Lee JH; Chu K; Gurkar AU; Kolev V; Zhang J; Namba T; Murphy ME; Newman DJ; Mandinova A; Clardy J; Lee SW
    Chem Biol; 2015 Sep; 22(9):1206-16. PubMed ID: 26320861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment.
    Lopes EA; Gomes S; Saraiva L; Santos MMM
    Curr Med Chem; 2019; 26(41):7323-7336. PubMed ID: 30444195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
    Zanjirband M; Rahgozar S
    Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small molecule compounds targeting the p53 pathway: are we finally making progress?
    Yu X; Narayanan S; Vazquez A; Carpizo DR
    Apoptosis; 2014 Jul; 19(7):1055-68. PubMed ID: 24756955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
    Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
    Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.
    Estrada-Ortiz N; Neochoritis CG; Dömling A
    ChemMedChem; 2016 Apr; 11(8):757-72. PubMed ID: 26676832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
    Patel S; Player MR
    Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
    Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
    Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of wild-type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53-1, a novel anticancer small-molecule.
    Soares J; Raimundo L; Pereira NA; Monteiro Â; Gomes S; Bessa C; Pereira C; Queiroz G; Bisio A; Fernandes J; Gomes C; Reis F; Gonçalves J; Inga A; Santos MM; Saraiva L
    Oncotarget; 2016 Jan; 7(4):4326-43. PubMed ID: 26735173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 dynamics in response to DNA damage vary across cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM.
    Stewart-Ornstein J; Lahav G
    Sci Signal; 2017 Apr; 10(476):. PubMed ID: 28442631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.
    Miller JJ; Gaiddon C; Storr T
    Chem Soc Rev; 2020 Oct; 49(19):6995-7014. PubMed ID: 32869798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule activators of the p53 response.
    Ladds MJGW; Laín S
    J Mol Cell Biol; 2019 Mar; 11(3):245-254. PubMed ID: 30689917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.